Cleopatra Hospitals Group S.A.E.
H1 2025 EARNINGS RELEASE

Cairo, Egypt | August 31st, 2025

Cleopatra Hospitals Group Reports Record 1H2025 Results

CHG posts a strong half-year performance driven by solid volume growth, continuing to demonstrate operating leverage with significant margin expansion across all levels

2Q2025 Financial & Operational Highlights[1]

EGP 1,763 mn Total Revenue (+48% y-o-y)	EGP 695 mn Gross Profit (+62% vs. 2Q24; 39% Margin; +3% margin expansion)
EGP 575 mn Adjusted EBITDA[2] (+71% vs. 2Q24; 33% Margin; +4% margin expansion)	EGP 432 mn EBIT (+88% vs. 2Q24; 25% Margin; +5% margin expansion)
EGP 289 mn Net Profit (+78% vs. 2Q24; 16% Margin; +3% margin expansion)	EGP 335 mn Normalized Net Profit[3] (+88% vs. 2Q24; 19% Margin; +4% margin expansion)
+27% Outpatient Consultations Volume Growth	+22% Inpatients Volume Growth
+14% ER Visits Volume Growth	+15% Surgical Procedures Volume Growth
+367,242 Cases Served[4] (+24% y-o-y)	EGP 0.20 Earnings Per Share (+78% vs. 2Q24 EPS)

1H2025 Financial & Operational Highlights[1]

EGP3,382 mn Total Revenue (+43% y-o-y)	EGP 1,309 mn Gross Profit (+52% vs. 1H24; 39% Margin; +2% margin expansion)
EGP 1,073 mn Adjusted EBITDA[2] (+55% vs. 1H24; 32% Margin; +3% margin expansion)	EGP 781 mn EBIT (+54% vs. 1H24; 23% Margin; +2% margin expansion)
EGP 522 mn Net Profit (+42% vs. 1H24; 15% Margin;)	EGP 605 mn Normalized Net Profit[3] (+54% vs. 1H24; 18% Margin; +1% margin expansion)
+17% Outpatient Consultations Volume Growth	+15% Inpatients Volume Growth
+10% ER Visits Volume Growth	+8% Surgical Procedures Volume Growth
+692,576 Cases Served[4] (+16% y-o-y)	EGP 0.36 Earnings Per Share (+42% vs. 1H24 EPS)

Cairo, 31st of August 2025

Cleopatra Hospital Group S.A.E. (CLHO.CA on the Egyptian Exchange), Egypt's leading private hospital group by number of hospital beds and number of operating hospitals, reported today its consolidated results for the period ended 30 June 2025.

---

[1] *Performance includes: CHC, CSH, NBH, & ASH, as well as East and West Cairo Polyclinics, El Katib Hospital, October Hospital, and Bedaya IVF.*
[2] *Adjusted EBITDA: Earnings before Interest, Tax, Depreciation and Amortization adjusted for provisions, impairments, LTIP, acquisitions expenses, pre-operating expenses and excluding contributions from other income.*
[3] *Normalized Net Profit adds back interest expense and excludes interest income from the consolidated Income Statement.*
[4] *Cases served includes number of inpatients, paid outpatient visits and ER visits.*

1H2025 Performance Highlights:

- **CHG delivered a strong top-line performance in 1H 2025**, supported by double-digit growth in patient volumes and greater case complexity. Quarterly revenues reached **EGP 1,763 mn** (+48% y-o-y) and half-year revenues totaled **EGP 3,382 mn** (+43% y-o-y). Growth was fueled primarily by rising inpatient and outpatient activity alongside a richer service mix across the Group's facilities.
- **Volume momentum was broad-based across the network.** All CHG hospitals achieved robust revenue growth of over **36% in 2Q 2025** and **33% in 1H 2025**, with particularly strong contributions from **El Katib** and **Cleopatra October Hospitals**. Organic growth initiatives translated into a **24% increase in cases served during the quarter** and **16% in the half year**, underpinned by outpatient consultations (+17% in 1H), inpatient admissions (+15%), and surgical procedures (+8%). The rapid development of the Group's **Centers of Excellence** attracted higher-complexity cases, reinforcing CHG's ability to manage more advanced treatment pathways.
- **Margins improved significantly alongside volume growth and case mix enhancements.** In 2Q 2025, gross profit margin expanded by 3pp, adjusted EBITDA margin by 4pp, and EBIT margin by 5pp. On a half-year basis, gross profit margin stood at 39% (+2pp), adjusted EBITDA margin at 32% (+3pp), and EBIT margin at 23% (+2pp). This margin expansion reflects enhanced operating leverage from rising patient volumes, a shift toward complex case mix, disciplined cost control, and targeted price adjustments implemented since January 2025.
- **Profitability also advanced sharply.** Net profit rose **78% y-o-y in 2Q 2025** and **42% in 1H 2025**, with net profit margin reaching **16% in 2Q** (+3pp) and maintained at **15% for the half year**. Excluding the effects of capital structure changes, normalized net income reached **EGP 335 mn in 2Q 2025** (+88% y-o-y; margin 19%, +4pp) and **EGP 605 mn in 1H 2025** (+54% y-o-y; margin 18%, +1pp), underscoring the impact of **volume growth, higher complexity, and improved service mix** on underlying profitability.

1H2025 Strategic Updates:

- **In H1 2025, CHG advanced its investment and modernization program, strengthening its Centers of Excellence (COE) and upgrading core facilities.** At Al Sherouk Hospital, a fully renovated inpatient ward was completed and launched in May. Cairo Specialized Hospital inaugurated a new **Bone Marrow and Organ Transplantation Center**, while Nile Badrawi Hospital introduced **Cleo Alfa Cure**, an integrated oncology center equipped with **AI-powered radiation therapy** and a multidisciplinary care model. These initiatives reinforce CHG's leadership in differentiated care and its commitment to improving quality and technology across its network.
- **The Group expanded its outpatient reach and referral network.** In Q2 2025, CHG launched a new **10-clinic polyclinic in Suez Governorate**, extending services beyond Greater Cairo for the first time. With specialties including neurosurgery, orthopedics, cardiology, ENT, and pediatrics, the facility reflects CHG's strategy of **diversifying its footprint** and **enhancing accessibility nationwide**, while complementing its core hospitals.
- **Polyclinic expansion continued in Greater Cairo.** Development of the **Maadi Polyclinic** is underway, with completion expected in early 2026. The multi-specialty facility will house **30 outpatient clinics**, advanced diagnostics (central lab, X-ray, CT), and physiotherapy services. As a key referral point to Nile Badrawi Hospital, it will expand access in residential hubs and strengthen CHG's **integrated care model**.
- **Cleopatra October Hospital accelerated its transformation into a musculoskeletal tertiary care hub.** Capacity expanded to **68 operational beds** following the addition of 23 new inpatient beds in mid-2025, alongside upgraded facilities including a new endoscopy center, renovated aqua therapy unit, expanded physiotherapy department, and new dialysis services. A fully operational cath lab will also be added, with **12 ICU beds scheduled by year-end** to bring total capacity to 80 beds. In parallel, the **200-bed Build-to-Suit extension** remains on track for 2026, positioning the hospital as a nearly 300-bed integrated medical complex and a destination for specialized care and medical tourism in West Cairo.
- **Preparations are underway for the launch of Cleopatra El Tagamoa Hospital, CHG's East Cairo flagship.** Opening in phases during 2025 with **100 beds at launch**, the facility will ramp up to **240 beds within its first year**. Anchored by multiple COEs and **state-of-the-art medical technologies**, the hospital will expand CHG's total network capacity by c.30% and further elevate standards of quality healthcare delivery in Egypt.

Management Comment

Cleopatra Hospitals Group delivered a strong first half of 2025, marked by solid financial and operational performance across all key metrics. Second-quarter revenues reached EGP 1,763.5 million, up 48% year-on-year, bringing first-half revenues to EGP 3.4 billion, supported by rising patient volumes, improved service mix, and enhanced case complexity.

Our network served more than 692,000 patients during the half year, reflecting not only higher inpatient and outpatient volumes but also stronger demand for more advanced and complex care. In Q2 alone, nearly 367,000 cases were treated – a 24% year-on-year increase – underscoring the scalability of our platform and the effectiveness of our investments in infrastructure, technology, and digital capabilities. These initiatives have improved patient access to quality healthcare, strengthened safety standards, and supported better outcomes across the Group.

Diversification across non-hospital verticals further enhanced performance. Polyclinics, diagnostics, and pharmacies all delivered growth, with pharmacies recording over 70% year-on-year revenue growth in Q2, complementing the performance of our core hospital operations.

We also advanced our long-term strategy of network expansion and medical technology investment. Al Sherouk Hospital reopened a renovated inpatient ward, while preparations for the Maadi Polyclinic continued ahead of its 2026 launch. Our Centers of Excellence portfolio was strengthened through two milestone additions: the Bone Marrow and Organ Transplantation Center at Cairo Specialized Hospital and Cleo Alfa Cure at Nile Badrawi Hospital – a fully integrated oncology facility equipped with AI-powered radiation therapy and a multidisciplinary care model, improving both quality and outcomes.

At the same time, we expanded our geographic footprint with the launch of a new 10-clinic polyclinic in Suez, extending our reach beyond Greater Cairo to serve new patient populations. Cleopatra October Hospital progressed in its transformation into a musculoskeletal hub, with new ICU and cath lab capacity set to come online this year and a 200-bed expansion on track for 2026. In East Cairo, Cleopatra El Tagamoa Hospital remains on schedule to open in 2025 with 100 beds at launch, scaling to 240 within the first year, expected to add approximately 30% to the Group's total capacity and significantly expand access to high-quality medical care.

Together, these initiatives reinforce CHG's commitment to building a broader, more technologically advanced, and patient-centered healthcare platform. Profitability advanced meaningfully during the period, driven by strong revenue growth, efficiency gains, and disciplined cost management. Our performance reflects the consistent execution of our roadmap and a focus on expanding access, improving safety, and delivering better patient outcomes.

At the same time, we remain focused on optimizing our balance sheet, as demonstrated by a return on equity of more than 40%. While we believe our share price continues to undervalue the strength of our underlying fundamentals, we are evaluating a range of strategic options to unlock and deliver greater value for our shareholders.

Looking ahead, we remain committed to long-term sustainable growth by investing in medical technology, expanding our network reach, and raising the quality of care across all facilities. With continued focus on outcomes, safety, and accessibility, we are well positioned to maintain momentum through the remainder of 2025 and beyond.

Dr. Ahmed Ezzeldin
Group CEO

Strategy Overview

Cleopatra Hospitals Group's growth strategy is anchored in a comprehensive, integrated model that combines organic initiatives with asset-light expansion to meet the evolving demands of Egypt's healthcare sector. Having consolidated a diverse base of private assets into a unified, scalable platform, the Group is now focused on unlocking the next phase of growth by more than doubling capacity and revenues through geographic diversification, outpatient expansion, and advanced service line development. During the second quarter of 2025, CHG continued to translate this vision into tangible progress, advancing its renovation program, strengthening its Centers of Excellence (COE) platform, and extending its outpatient footprint into new geographies.

CHG's Centers of Excellence

A central pillar of this strategy is the continued investment in CHG's Centers of Excellence, designed to deliver comprehensive care across high-value specialties. In 1H2025, the Group inaugurated two major additions to its Centers of Excellence portfolio: a Bone Marrow and Organ Transplantation Center, currently housed at Cairo Specialized Hospital, and Cleo Alfa Cure at Nile Badrawi Hospital, a state-of-the-art oncology facility equipped with AI-powered radiation therapy and a multidisciplinary care model. This development in the group allows for further advancements to the Group's Oncology Centres of Excellence's capabilities.

Alongside service line development, and in line with its asset-light model, CHG is also scaling its outpatient platform to extend access and generate incremental referral flows to its hospitals. During Q2 2025, CHG launched a new fully equipped polyclinic in Suez Governorate, comprising 10 clinics across specialties such as neurosurgery, orthopedics, cardiology, ENT, and pediatrics. This marked the Group's first outpatient expansion beyond Greater Cairo and demonstrates its strategy of diversifying its geographic footprint to capture unmet demand in underserved, high-growth regions.

Preparations are also underway for the launch of the Maadi Polyclinic in the beginning of 2026, further strengthening referral linkages across the network – specifically to Nile Badrawi Hospital – and reinforcing CHG's Polyclinics platform. The facility is a seven-floor multi-specialty polyclinic, offering 30 specialty clinics supported by advanced diagnostics (central lab, X-Ray and CT scan) and physiotherapy services. The facility's layout is designed to maximize patient convenience and operational efficiency, with clinics covering specialties such as ENT, GIT, Urology, and Cardiology. Once operational, the Maadi Polyclinic will reinforce CHG's outpatient platform and act as a critical feeder to its inpatient network.

On the infrastructure front, the Group continued its investment and modernization program, completing the renovation and relaunch of an inpatient ward at Al Sherouk Hospital in May 2025, which is expected to further bolster inpatient revenues in the second half of 2025. These initiatives reinforce CHG's leadership in complex, differentiated care while supporting stronger referral pathways and improved case mix across the network.

Together, these initiatives demonstrate CHG's consistent execution of its strategic roadmap: reinforcing Centers of Excellence, enhancing patient access through outpatient expansion, and pursuing scalable, asset-light growth opportunities to create long-term value and cement its position as Egypt's leading private healthcare platform.

Cleopatra October Hospital: On Track to Become a 300-Bed Integrated Medical Hub



Cleopatra October Hospital continues to advance on its transformation journey, having evolved in 2024 into a high-performing musculoskeletal tertiary care center with consistently strong performance across key metrics. Significant upgrades to the existing facility have already been realized since CHG assumed operations in Q4 2023. The first phase of renovations is complete, including the construction of internal bridges and lifts to enhance patient flow. The hospital has also inaugurated its new endoscopy center, renovated its aqua therapy unit – now featuring seven pools – and expanded the physiotherapy department with 12 additional beds across six double rooms. Dialysis services have also commenced with seven operational machines. Further capacity expansion was realized in mid-August 2025, with the addition of 23 inpatient beds, increasing the hospital’s total operational bed capacity to 68 beds. A state-of-the-art cath lab and a further 12 ICU beds are expected to come online, within the third quarter of 2025, bringing the hospital’s total operational capacity to 80 beds.

Meanwhile, construction of the 200-bed Build-to-Suit extension remains on track for handover in 2026. The extension is being fully constructed and finished by the property owner, with CHG investing solely in medical and non-medical equipment. Once complete, Cleopatra October will be transformed into a nearly 300-bed integrated medical complex anchored by multiple Centers of Excellence, including upcoming divisions in Sports Medicine, Pediatric Rehabilitation, Oncology, Transplantation, Gynecology, and Renal Therapy – reinforcing its position as a destination for specialized care and medical tourism in West Cairo.

Cleopatra El Tagamoa Hospital: Flagship Facility Nears 2025 Launch

Cleopatra El Tagamoa Hospital continues to make strong progress as it moves through the final stages of testing, commissioning, and furnishing in preparation for its planned 2025 launch. The hospital will open in a phased approach, starting with 100 operational beds and scaling up to 240 beds within the first year to drive operational efficiency and margin optimization. Once fully ramped up, the facility is expected to contribute approximately 30% of CHG's total bed capacity and revenue base, with utilization levels anticipated to mirror those of Cleopatra Hospital. As CHG's East Cairo flagship, the hospital will house advanced technologies and Centers of Excellence – reflecting the Group's commitment to strategic growth and quality care.

Financial Review

Contribution by Segment (1H25)



Revenue by Hospital (1H25)



**Polyclinic revenue includes both East and West Cairo Polyclinics (CHG for medical services).*

Revenue Analysis

During 1H2025, the Group delivered consolidated revenues of EGP 3,382mn, up from EGP 2,372mn in 1H2024. On a quarterly basis, revenues reached EGP 1,763mn, reflecting robust growth of 48% compared to 2Q2024. This strong performance was underpinned by higher volumes across all core services, supported by optimized patient case mixes and targeted price adjustments implemented in January 2025 in line with the Group's commercial strategy. Operational momentum was also evident in volumes, with total cases served rising 16% y-o-y to a record 693k in 1H2025.

Semi Annual Revenue Progression – in EGP Mn

EGP mn	1H22	2H22	1H23	2H23	1H24	2H24	1H25
Total Revenues	1,242	1,373	1,585	2,011	2,372	3,048	**3,382**
Y-o-y Growth	*-3%*	*8%*	*28%*	*46%*	*50%*	*52%*	***43%***

Magnified Core Business Growth

	Volumes			Revenues (in EGP mn)		
	2Q24	2Q25	%	2Q24	2Q25	%
Outpatient Visits	237k	300k	*27%*	107	155	*45%*
Surgeries – Patients	6,475	7,934	*23%*	248	328	*32%*
Surgical Procedures	9,376	10,742	*15%*			
Inpatients	15,324	18,682	*22%*	257	395	*53%*
Emergency Visits	42,680	48,484	*14 %*	46	62	*36%*
Catheterization Lab	1,221	1,523	*25%*	93	122	*32%*
Laboratory Tests	432k	563k	*30%*	116	191	*65%*
Radiology Tests	76k	97k	*28%*	78	126	*61%*

Revenue Breakdown by Segment

CHG's consolidated revenues were strongly driven by inpatient services and surgical procedures, which contributed 22% and 19% of total revenues in 2Q2025, and 23% and 18% in 1H2025, respectively. The inpatient segment delivered strong performance, with revenues growing 53% y-o-y in 2Q2025, supported by a 22% increase in volumes and a 26% rise in average revenue per patient (ARP). This momentum translated into 51% growth in 1H2025 versus 1H2024, fueled by a 15% increase in inpatient volumes and 32% rise in ARP during the first six months of the year.

Surgical revenues also maintained robust momentum, rising 32% y-o-y in both 2Q2025 and 1H2025. Growth was underpinned by higher ARP and volumes, with a growing share of complex procedures being treated through CHG's expanding Centers of Excellence. These facilities have enhanced patient referral pathways and strengthened surgical case sourcing, while targeted price adjustments ensured profitability alongside service quality. Management remains confident in sustaining this trajectory through the remainder of 2025.

Similarly, catheterization procedures continued to perform strongly on the back of the Group's Cardiology Center of Excellence, contributing 7% of consolidated revenues in both 2Q2025 and 1H2025. Growth was driven by a 25% increase in quarterly procedures

Number of Surgical Procedures
(Rev/Procedure)



Number of Paid Consultations
(Rev/Visit)



Number of Inpatients
(Rev/Inpatient)



Number of ER Visits
(Rev/visit)



Number of Catheterizations
(Rev/catheterization)

All KPI figures refer to the consolidation of all CHG hospitals as well as the Group's East and West Cairo Polyclinics) and excludes Bedaya while taking into account elimination entries.

and a 17% rise on a half-year basis, coupled with ARP growth of 6% in 2Q2025 and 5% in 1H2025. These results highlight the success of CHG's integrated approach in scaling specialized service lines while delivering consistent, high-quality care.

In parallel, emergency and outpatient cases each contributed 12% to the Group's consolidated revenue in both the second quarter and first 6 months of 2025. Emergency revenues grew by 39% y-o-y in 1H2025, supported by a 26% rise in ARP. Outpatient services also delivered solid performance, with revenues rising 33% in the first half of the year, driven by a 14% improvement in ARP.

Diagnostics continued to be a major growth driver, with laboratory and radiology revenues increasing by 54% and 56%, respectively, in 1H2025. This growth was further supported by ARP expansions of 27% in laboratory tests and 26% in radiology services. The diagnostics segment remains a cornerstone of CHG's strategy, enabling the Group to capture a greater share of the patient journey and reinforce its position as a comprehensive, one-stop-shop healthcare provider.

Revenue Breakdown by Facility

Cleopatra Hospital:
Cleopatra Hospital (CHC) remained the Group's largest revenue contributor in 1H2025, accounting for 32% of consolidated revenues at EGP 1,109mn, up 33% y-o-y. Growth was broad-based across all segments, with inpatient services standing out, delivering a 41% revenue increase supported by a 14% rise in volumes. This performance was fueled by the successful ramp-up of CHC's Centers of Excellence and further reinforced by the recently renovated inpatient and ICU wards. Notably, the Cardiovascular Center of Excellence emerged as a key growth engine, with cath lab volumes advancing 19% y-o-y. Leveraging its expanding Centers of Excellence to capture a greater share of the patient journey, CHC is well positioned to sustain its strong growth trajectory.

Cairo Specialized Hospital:
In 1H2025, Cairo Specialized Hospital (CSH) generated EGP 761mn in revenues, representing 22% of CHG's consolidated top line and a 46% increase y-o-y. This exceptional performance was underpinned by a 17% rise in total cases served, with notable momentum across emergency (+18%), outpatient (+17%), and inpatient (+15%) services. CSH's growth was further accelerated by the rapid scale-up of its Nephrology Center of Excellence, where dialysis procedures expanded more than fourfold, underscoring the hospital's ability to capture rising demand in specialized care.
The expansion of the hospital's Centers of Excellence led to a three-percentage points enhancement in gross profit margin which trickled down to the EBITDA margin recording an impressive 37% and 30%, respectively.

Al Sherouk Hospital:
ASH delivered exceptional year-on-year growth in 1H2025, with top-line revenue surging by 43% to reach EGP 517mn, overtaking NBH to become the Group's third-largest revenue contributor. ASH's growth in 1H2025 was driven by an increase in cases served, which rose by 13% during the period, coupled with enhanced case mix profitability levels. The hospital saw an uptick in outpatients and inpatients served, which both grew by 14%. These volumes reflect the hospital's ability to maintain growth on the back of management's investments in its medical capabilities throughout the first half of 2025. These initiatives drove a four-percentage point improvement in gross profit margin versus 1H2024, a positive trend expected to continue over the remainder of the year, further reinforcing ASH's financial standing. The hospital's progress was also supported by the continued execution of its renovation program, underscoring its commitment to elevating patient care.

Nile Badrawi Hospital:
Nile Badrawi Hospital (NBH), which accounts for 15% of the Group's consolidated top line, delivered impressive results in 1H2025, with revenue growth of 39% to reach EGP 514mn. NBH's Oncology and Cardiovascular Centers of Excellence were key drivers of

this success. The hospital witnessed 17% in cases served in 1H2025. This performance translated into a two-percentage point expansion in EBITDA margin, reaching 26% compared to 24% in 1H2024. With the continued ramp-up of its newly launched Centers of Excellence, NBH is well-positioned to sustain – and potentially enhance – this margin improvement through year-end.

Cleopatra October Hospital:
Cleopatra October Hospital has undergone a remarkable transformation over the past year and a half, evolving from a dedicated physiotherapy center into a fully-fledged tertiary care facility anchored by Orthopedic and Neurology Centers of Excellence. In 1H2025, the hospital contributed 5% to the Group's consolidated revenue, generating EGP 184mn – an 87% y-o-y increase that highlights its strong ramp-up momentum. This performance reflects the hospital's ability to attract a growing patient base, supported by the rapid development of its Centers of Excellence and a surge of more than 125% in total cases served, with volumes across all major segments rising by over 80%. Furthermore, the recent inauguration of its Endoscopy Center and dialysis services, along with the expansion of the physiotherapy department by 12 additional beds and the addition of 23 inpatient beds, is expected to further support revenue growth in the second half of 2025.

Profitability Analysis

Cost of Goods Sold & Gross Profit

During 2Q2025 and 1H2025, CHG recorded total cost of goods sold (COGS) amounting to EGP 1,068mn and EGP 2,073mn, signifying increases of 40% and 37% respectively. On a half-year basis, revenue growth of 43% outpaced the increase in COGS by five percentage points, underscoring the Group's operating leverage.

As a result, the COGS-to-sales ratio fell to 61% in both periods, down from 64% a year earlier. This translated into gross profit margin expansion of three percentage points year-over-year to 39% in 2Q2025, and a two-point improvement to 39% in 1H2025. This margin uplift reflects management's continued success in optimizing key cost drivers. Proactive measures to control salaries, wages, and consultant fees effectively offset inflationary pressures on medical consumables, enabling CHG to safeguard profitability while maintaining high service quality and delivery standards.



In terms of COGS, most cost components demonstrated notable improvement, reflecting the Group's ability to optimize its case mix. Doctor fees saw a two-percentage-point improvement in the Doctor Fees-to-Revenue ratio, settling at 12% in 1H2025 and 13% in 2Q2025. Similarly, the Salaries and Wages-to-Revenue ratio improved by one percentage point y-o-y in 1H2025, reaching 15% compared to 16% in 1H2024. These trends highlight CHG's commitment to driving sustainable productivity gains across its operations.

Conversely, medical consumables exerted moderate pressure on margins due to a low-base effect, following previously secured competitive procurement rates and inventory stockpiling during earlier years of market volatility. Consequently, the medical

CHC Revenue Growth (EGP mn)



CSH Revenue Growth (EGP mn)



ASH Revenue Growth (EGP mn)



NBH Revenue Growth (EGP mn)



AKH Revenue Growth (EGP mn)



consumables-to-revenue ratio rose by two percentage points to 23% in both 2Q2025 and 1H2025. Nevertheless, CHG remains focused on proactively navigating macroeconomic challenges, safeguarding profitability, and sustaining high standards of service quality.

G&A Expenses



In 2Q2025, G&A expenses reached EGP 257mn, up 33% y-o-y but down 2% q-o-q. The G&A-to-sales ratio declined to 14.6% in 2Q2025 from 16.3% in 2Q2024, reflecting improved operating leverage. This offset the impact of pre-operating expenses related to the upcoming launch of Cleopatra El Tagamoa Hospital, which had temporarily elevated the cost base and driven higher G&A in 1Q2025. On a semi-annual basis, G&A expenses increased 49% y-o-y; however, the G&A-to-sales ratio remained stable at 15%, underscoring management's ability to maintain financial discipline and effectively execute cost-control initiatives.

EBIT & EBITDA

CHG's adjusted EBITDA for the second quarter stood at EGP 575mn, marking an impressive 71% growth while improving margins by 4% in comparison to 2Q2024. Over a half-year period, the Group achieved an unprecedented EBITDA of EGP 1,073mn, reflecting growth rate of 55% at an expanded margin of 32% relative to 1H2024. Similarly, the Group reported an EBIT of EGP 432mn, up to 88% compared to 2Q2024, with a higher by 5% margin of 25%. Over and above, for 1H2024 the Group saw an EBIT of EGP 781mn, an increase of 54% y-o-y, while realizing an expanded EBIT margin of 23% compared to the first half of 2024.

Consequently, all CHG facilities delivered margin efficiencies in both 1H2025 and 2Q2025, reflecting the Group's operational excellence. It is worth noting that Cleopatra October Hospital, the Group's newest facility, achieved double-digit EBITDA margins of 12% in 2Q2025 and 9% in 1H2025, compared to -2% and 2% in the same periods of 2024, respectively.

Net & Normalized Net Profits

CHG's consolidated net profit for 1H2025 reached EGP 522mn, up 42% from the same period in 2024, with the associated margin remaining stable at 15%. On a quarterly basis, net profit came in at EGP 289mn in 2Q2025, reflecting strong growth of 78% y-o-y, while the margin expanded three percentage points to 16%.

Despite temporary pressures, the Group's recent capital structure optimization limited the impact on profitability by containing the increase in interest expenses y-o-y and enabling efficiency gains to filter through to the bottom line. Nonetheless, interest expenses rose by 125% during the quarter and 115% in the half year, reflecting financing needs tied to ongoing expansion.

Excluding this impact, normalized net income stood at EGP 335mn in 2Q2025, up 88% y-o-y, and EGP 605mn in 1H2025, up 54% y-o-y. This translates into normalized net profit margins of 19% for the quarter and 18% for the half year, underscoring the Group's underlying operational strength.









Balance Sheet Analysis

CAPEX & Financing

The Group continued to prioritize investment in expanding and upgrading its network, with total CAPEX outlays in 1H2025 reaching approximately EGP 1.3 billion. Around 96% of this amount relates to assets purchased for projects currently under construction. The largest share of CAPEX was allocated to Cleopatra El Tagamoa Hospital (c. EGP 823.5 million, including capitalized interest), followed by c. EGP 397 million directed toward the renovation programs at Cleopatra Hospital, Cleopatra October, Nile Badrawi, and Cairo Specialized Hospitals.

Reported net financial debt in June 2025 amounted to EGP 2.9bn compared with EGP 2.0bn in FY2024. This surge aligns with the Group's expansion plan and investments in its new East Cairo flagship, Cleopatra El Tagamoa Hospital, as well as the ramp-up approach applied with Cleopatra October Hospital. Additionally, the renovation programs at Cleopatra Hospital, Cleopatra October, NBH, and CSH have also received significant attention from the Group's investments. Net debt includes EGP 2.7bn in non-current borrowings and EGP 475mn in current borrowings, offset by EGP 486mn in cash and cash equivalents. The application of IFRS 16 to leases contributed EGP 187mn to net financial debt as of 30 June 2025, of which EGP 133mn was non-current lease debt and EGP 54mn was current lease debt. These lease liabilities pertain to CHG's management and Polyclinic buildings.

–Ends–

ABOUT CLEOPATRA HOSPITALS GROUP S.A.E.

The Group is the largest private hospital group in Egypt by number of hospital beds and number of operating hospitals. The company holds majority stakes and operates seven leading hospitals in the Greater Cairo Area: Cleopatra Hospital, Cairo Specialized Hospital, Nile Badrawi Hospital, Al Sherouk Hospital, El Katib Hospital, Cleopatra El Tagamoa Hospital, and Cleopatra October Hospital offering a full array of general, emergency healthcare services and rehabilitation services. The Group also operates two polyclinics located in strategic neighbourhoods of East and West Cairo and holds a majority stake in Bedaya for Medical Services, Egypt's leading IVF and Fertility Centre.

Shareholder Information

EGX: CLHO.CA
Listed: June 2016
Shares Outstanding: 1,445 million

For further information, please contact:

Cleopatra Hospitals Group S.A.E.

Hassan Fikry
Chief Strategy & New Businesses Officer
hassan.fikry@cleohc.com

Farah Sami
Corporate Strategy and IR Manager
farah.sami@cleohc.com

ir@cleohc.com

Shareholder Structure

(as of June 2025)



Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management's ("Management") current views of future events, are based on Management's assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management's ability to timely and accurately identify future risks to our business and manage the risks mentioned above. Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.

Consolidated Statement of Income

All figures in EGP mn	2Q2024	2Q2025	% Change	1H2024	1H2025	% Change
Revenues	1191.2	1763.5	*48.0%*	2372.4	3382.1	*42.6%*
Cost of sales	(763.0)	(1068.4)	*40.0%*	(1508.5)	(2072.8)	*37.4%*
Gross profit	**428.2**	**695.1**	***62.3%***	**863.8**	**1309.4**	***51.6%***
Gross Profit Margin	*36%*	*39%*		*36%*	*39%*	
General & administrative expenses	(193.8)	(257.2)	*32.7%*	(349.6)	(519.9)	*48.7%*
Cost of acquisition activities	0.5	0.0	*-100.0%*	-	(0.3)	
Provisions	(7.1)	(11.3)	*58.0%*	(12.4)	(17.9)	*44.4%*
Other income	2.7	5.7	*108.3%*	5.0	9.4	*87.7%*
Intangible Assets Write Off	-	-		-	-	
Discontinued Operations	-	-		-	-	
EBIT	**230.5**	**432.3**	***87.5%***	**506.9**	**780.7**	***54.0%***
EBIT Margin	*19%*	*25%*		*21%*	*23%*	
Interest income	10.0	12.0	*20.1%*	23.1	28.0	*21.3%*
Interest expense	(27.3)	(61.3)	*125.0%*	(48.6)	(104.5)	*115.0%*
Profit before tax	**213.3**	**383.1**	***79.6%***	**481.4**	**704.3**	***46.3%***
PBT Margin	*18%*	*22%*		*20%*	*21%*	
Income tax	(55.3)	(96.0)	*73.6%*	(106.5)	(174.3)	*63.6%*
Deferred tax	4.1	2.2	*-47.5%*	(8.1)	(8.5)	*4.5%*
Net profit after tax	**162.1**	**289.3**	***78.4%***	**366.8**	**521.5**	***42.2%***
Net Profit Margin	*14%*	*16%*		*15%*	*15%*	
Distributed as follows:						
Shareholders of the company	143.0	250.4	*75.2%*	325.2	451.0	*38.7%*
Minority rights	19.2	38.9	*102.6%*	41.6	70.6	*69.7%*
Profit for the period	**162.1**	**289.3**	***78.4%***	**366.8**	**521.5**	***42.2%***

Consolidated Statement of Comprehensive Income

All figures in EGP mn	2Q2024	2Q2025	% Change	1H2024	1H2025	% Change
Net Profit	162.1	289.3	*78.4%*	366.8	521.5	*42.2%*
Other comprehensive income	-	-		-	-	
Total comprehensive income for the year	**162.1**	**289.3**	***78.4%***	**366.8**	**521.5**	***42.2%***
Total comprehensive income attributable to:						
Owners of the company	143.0	250.4	*75.2%*	325.2	451.0	*38.7%*
Non-controlling interest	19.2	38.9	*102.6%*	41.6	70.6	*69.7%*
Total comprehensive income for the year	**162.1**	**289.3**	***78.4%***	**366.8**	**521.5**	***42.2%***

Consolidated Statement of Financial Position

All figures in EGP mn	31 December 2024	30 June 2025
Non-current assets		
Fixed assets	4,642.2	5,795.4
Intangible assets	405.2	404.2
Right of use	75.6	430.7
Payment under investment	-	-
Investment in associates	8.5	8.5
Total non-current assets	**5,131.6**	**6,638.9**
Current assets		
Inventory	320.5	288.2
Accounts receivables	1,046.8	1,325.6
Other receivables and debit balances	597.2	454.5
Due from related parties	20.5	20.5
Treasury bills	-	-
Cash	473.2	486.5
Total current assets	**2,458.2**	**2,575.3**
Total assets	**7,589.8**	**9,214.1**
Equity		
Share capital	722.7	722.7
Treasury Shares	(5.6)	(5.6)
Reserves	97.3	117.9
Retained earnings	2,048.7	2,336.9
Long term incentive plan	36.5	96.5
Equity attributable to the parent company	**2,899.6**	**3,268.4**
Non-controlling interest	278.2	344.6
Total equity	**3,177.8**	**3,613.0**
Non-current liabilities		
Non-current portion of borrowings	1,908.8	2,698.8
Creditors and other credit balances - non-current portion	-	-
Non-current portion of lease liability	62.4	133.1
Deferred tax liabilities	116.3	124.8
Total non-current liabilities	**2,087.5**	**2,956.7**
Current liabilities		
Provisions	73.1	65.4
Creditors and other credit balances	1,523.4	1,874.8
Current Portion of Borrowings	439.7	474.7
Current portion of lease liability	46.8	54.4
Other Liabilities	42.5	42.5
Current income tax	199.0	132.7
Total current liabilities	**2,324.5**	**2,644.4**
Total liabilities	**4,412.0**	**5,601.1**
Total liabilities & shareholders' equity	**7,589.8**	**9,214.1**

Consolidated Statement of Cash Flow

All figures in EGP mn	30 June 2024	30 June 2025
Cash flow from operating activities:		
Profit before tax	481.4	704.3
Adjustments for:		
Depreciation	87.3	108.8
Right of use depreciation	-	-
Amortization of intangible assets	1.0	3.0
Allowance for impairment of current assets	17.7	42.4
Provision	(2.3)	(7.6)
Capital gain/Loss	(0.5)	(2.1)
Credit / Debit Interest	30.7	61.4
Changes in current tax liability	(92.7)	(240.6)
Loss In Investments in subsidiaries	-	-
Share-based payments financial liabilities	35.1	60.0
Lease Write Off	-	-
Intangible Assets Write off	-	-
Operating profits before changes in assets and liabilities	**557.7**	**729.7**
Changes in working capital:		
Changes in Inventories	(48.5)	30.3
Change in trade receivables, debtors and other debit balances	(406.4)	(213.5)
Changes in Due from related parties	0.2	-
Change in trade and other payables	170.7	101.4
Employee Incentive Plan	-	-
Change in lease	(5.5)	9.2
Net cash flows generated from operating activities	**268.2**	**657.0**
Cash flow from investment activities:		
Proceeds from sale of fixed assets	0.6	2.6
Fixed assets purchased	(83.8)	(49.8)
PUC purchased	(613.6)	(1,212.8)
Advance payment for purchase of fixed assets	(270.1)	-
Fixed assets Suppliers	-	-
Payments under investment	-	-
Credit Interest Collected	17.6	26.4
Paid for Investment Associates	-	-
Net cash flows used in investing activities	**(949.4)**	**(1,233.5)**
Cash flow from financing activities:		
Treasury Shares	(16.8)	-
Dividends paid out	(113.2)	(146.3)
Cash Proceed from Overdraft	671.2	731.0
Cash Paid to Overdraft	(599.4)	(705.1)
Interest paid	(41.6)	(88.4)
Receipts from borrowings	720.1	827.6
Repayment of Borrowings	(50.2)	(28.5)
Net cash flow from financing activities	**570.1**	**590.3**
Net change in cash & cash equivalents during the year	**(111.0)**	**13.7**
Cash and cash equivalents at the beginning of the year	362.5	477.8
Cash And Cash /equivalent In Acquired Subsidiaries at Beg. Of The Period	-	-
Cash & cash equivalents at the end of the year	**251.5**	**491.5**